Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy

This publication has 8 references indexed in Scilit:

• Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
  Journal of Clinical Oncology, 1987
• The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer
  American Journal of Obstetrics and Gynecology, 1986
• CA 125 Serum Levels Correlated With Second-Look Operations Among Ovarian Cancer Patients
  Obstetrics & Gynecology, 1986
• Die klinische Bedeutung des Tumormarkers CA-125 für die präoperative Diagnostik und die postoperative Nachbetreuung von Patientinnen mit malignen Ovarialtumoren
  Geburtshilfe und Frauenheilkunde, 1985
• A pilot study of CHAC-1
  Cancer Treatment Reviews, 1985
• Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker
  British Journal of Cancer, 1984
• RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA
  The Lancet, 1984
• A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
  New England Journal of Medicine, 1983